View article

In a phase I study, ten ovarian cancer patients with extensive metastatic disease despite chemotherapy were immunized three to eight times subcutaneously with the synthetic form of the immunodominant disaccharide ([beta] Gall [heavy triangle-headed rightwards arrow] 3 [alpha] GalNAc) of the Thomsen-Friedenreich antigen conjugated to KLH (TF [alpha]-KLH) plus DETOX adjuvant. Six patients were given a" low" dose of TF [alpha]-KLH (100 ([micro] g/injection) and four patients were given a" high" dose (500 [micro] g/injection). AH patients received a single low-dose cyclophosphamide treatment (200 mg/m2 iv) 3 days prior to commencement of the series of immunizations. Immunizations were 2 weeks apart. Little or no toxicity was noted. As expected, all patients (prior to immunization) had naturally occurring IgM antibodies against the synthetic TF [alpha] hapten. None of the patients had detectable pre-existing …